Athira Pharma (ATHA) Projected to Post Earnings on Thursday

Athira Pharma (NASDAQ:ATHA) is anticipated to announce its earnings results on Thursday, February 20th. Analysts expect the company to announce earnings of ($0.45) per share for the quarter.

Athira Pharma Trading Down 0.7 %

Shares of ATHA opened at $0.45 on Thursday. The stock’s 50 day moving average is $0.55 and its two-hundred day moving average is $1.03. Athira Pharma has a twelve month low of $0.41 and a twelve month high of $4.30. The firm has a market capitalization of $17.36 million, a PE ratio of -0.16 and a beta of 2.97.

About Athira Pharma

Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies.